This phase 2 trial evaluated three low-dose intensity subcutaneous bortezomib-based treatments in patients ⩾ 75 years with newly diagnosed multiple myeloma (MM). Patients received subcutaneous bortezomib plus oral prednisone (VP, N = 51) or VP plus cyclophosphamide (VCP, N = 51) or VP plus melphalan (VMP, N = 50), followed by bortezomib maintenance, and half of the patients were frail. Response rate was 64% with VP, 67% with VCP and 86% with VMP, and very good partial response rate or better was 26%, 28.5% and 49%, respectively. Median progression-free survival was 14.0, 15.2 and 17.1 months, and 2-year OS was 60%, 70% and 76% in VP, VCP, VMP, respectively. At least one drug-related grade ⩾ 3 non-hematologic adverse event (AE) occurred in 22% of VP, 37% of VCP and 33% of VMP patients; the discontinuation rate for AEs was 12%, 14% and 20%, and the 6-month rate of toxicityrelated deaths was 4%, 4% and 8%, respectively. The most common grade ⩾ 3 AEs included infections (8-20%), and constitutional (10-14%) and cardiovascular events (4-12%); peripheral neuropathy was limited (4-6%). Bortezomib maintenance was effective and feasible. VP, VCP and VMP regimens demonstrated no substantial difference. Yet, toxicity was higher with VMP, suggesting that a two-drug combination followed by maintenance should be preferred in frail patients.
INTRODUCTION
In recent years, the introduction of novel agents such as immunomodulatory drugs and the proteasome inhibitor bortezomib, associated with standard chemotherapy, has changed the management of multiple myeloma (MM) and extended survival. 1 Data from the SEER (Surveillance, Epidemiology, and End Results) registry showed a significant trend toward a better 5-year survival for patients diagnosed between 2003 and 2007, whereas no survival improvement was seen in older patients (⩾ 65 years). 2 The global population is rapidly aging. The proportion of the population aged 65 years or over is expected to increase in all European countries, from 17.08% in 2008 to 29.95% in 2060; in particular, the population aged 80 years or over is expected to almost triple. 3 Approximately one-third of patients with myeloma at diagnosis are older than 75 years and at least 30% are frail, because of the presence of concomitant disease, abnormal laboratory test results and symptoms or signs of disability that may complicate the presentation and management of myeloma. 4, 5 Although the majority of myeloma diagnoses and myeloma-related deaths occur in subjects over 65 years, elderly frail patients are not fully characterized and they are underrepresented in clinical trials. Thus, frail patients usually receive regimens tested in fit patients, which may be too toxic for them and cause early treatment discontinuation, low efficacy and impaired quality of life.
Today, bortezomib-melphalan-prednisone (VMP) and melphalan-prednisone-thalidomide (MPT) are the reference treatments for elderly myeloma patients. 6, 7 Nevertheless, the efficacy of these regimens was less evident in patients aged 75 years or over. VMP induced a shorter overall survival (OS) in patients older than 75 years in comparison with younger patients (median 32.9 vs 50.7 months); 8 the incidence of any grade 3-4 adverse events (AEs) was 91%; and bortezomib discontinuation rate owing to AEs was 34%. 9 Similar results have been reported with MPT: the median progression-free survival (PFS) of patients over 75 years (10 months with MPT and 6 months with MP) was shorter compared with younger patients, and no improvement was observed in OS. 10 In another trial including patients over 75 years, MPT led to a response rate of 62% and a median PFS of 24 months, but the median duration of treatment was 13.5 months and 45% of patients discontinued treatment for AEs. 11 Furthermore, advanced age (hazard ratio 1.44, P o 0.001), the occurrence of severe cardiac, gastrointestinal AEs and infections (hazard ratio 2.53, P o 0.001) and drug discontinuation (hazard ratio 1.67, P = 0.01) predicted a higher risk of death in newly diagnosed myeloma patients treated with melphalan-prednisone, either alone or in combination with thalidomide and/or bortezomib. This was particularly evident with the use of more complex combinations including the association of bortezomib and thalidomide. In fact, different trials did not show a substantial advantage with multidrug regimens over less intensive combinations, because multidrug combinations are often associated with higher toxicity rates and worse quality of life, especially in community-based populations. 12, 13 The morbidity associated with dexamethasone-based regimens was significantly higher compared with the one reported with prednisone, especially in terms of infections and gastrointestinal complications. 14 These findings raise the question of whether a lower dose intensity treatment with two-drug combinations may improve tolerability, preserving efficacy, in very elderly and frail patients, and thus should be preferred to three-drug combinations.
To address this question, we designed a multicenter, communitybased study to examine the efficacy and safety of weekly subcutaneous bortezomib plus continuous low-dose prednisone (VP) or cyclophosphamide-prednisone (VCP) or melphalan-prednisone (VMP) in patients over 75 years of age with newly diagnosed MM.
PATIENTS AND METHODS
Patients aged ⩾ 75 years old (or younger with abnormal organ function), unsuitable for standard treatments or usually excluded from clinical protocols with standard inclusion/exclusion criteria, with measurable disease and a Karnofsky performance status ⩾ 50%, were enrolled. 15 Diagnosis of myeloma was made using the standard criteria. 16 Exclusion criteria included grade ⩾ 2 peripheral neuropathy; creatinine clearance o20 ml/min; absolute neutrophil count o1000/μl; platelets o80 000/μl; aspartate aminotransferase or alanine aminotransferase 42.5 times upper limit of normal; or total bilirubin 41.5 times upper limit of normal.
All patients provided written informed consent. Review boards at each participating site approved the study, which was conducted in accordance with the Declaration of Helsinki. This trial is registered at www.clinicaltrials. gov, NCT01190787.
Study design
This phase 2, non-randomized study was conducted at 23 centers. Patients were sequentially enrolled in either one of the three, independent bortezomib cohorts, namely VP or VCP or VMP. Subjects were recruited from October 2010 to August 2012; the cutoff date was 15 March 2014.
The primary objective was to determine the rate of very good partial response (VGPR) in patients with newly diagnosed MM treated with VP, VCP and VMP regimens.
Secondary objectives included safety and tolerability, overall response rates (ORR), time to response, time to progression, PFS and OS.
Study treatment
Patients were enrolled in three cohorts of treatment with VP, VCP and VMP. Treatment consisted of nine 28-day cycles of induction therapy with subcutaneous bortezomib 1.3 mg/m 2 on days 1, 8, 15 and 22 plus oral prednisone 50 mg every other day (VP) or VP plus oral cyclophosphamide 50 mg every other day (VCP) or plus oral melphalan 2 mg every other day (VMP), followed by maintenance with subcutaneous bortezomib on days 1 and 15 until progression.
Patients could receive supportive therapy including bisphosphonates, granulocyte colony-stimulating factor, erythropoietin and transfusions, as necessary. Prophylactic acyclovir for herpes zoster was recommended.
Assessments
At baseline a geriatric assessment (GA) was performed. The geriatric assessment consisted of three tools: Katz's Activities of Daily Living (ADL) and Lawton's Instrumental Activities of Daily Living (IADL) scores to assess self-care activities, tasks of household management and independence status; Charlson comorbidity index to estimate the number and the severity of comorbidities. 17, 18 AEs were graded according to NCI-CTCAE (National Cancer InstituteCommon Terminology Criteria for Adverse Events) version 3.0. 19 Response was assessed before every treatment cycle. Response categories were based on the International Myeloma Working Group uniform response criteria. 16 
Statistical methods
Based on the primary objective (VGPR rate), sample size was estimated at the significance level of α = 0.05, power of 80%, a null hypothesis VGPR rate of 10% and an alternative hypothesis VGPR rate of 25%.
Based on Simon's optimal two-stage design, 20 for each cohort 43 patients were required (18 patients in the first phase, 25 in the second one). Assuming 15% of patients lost to follow-up, to obtain 129 responseevaluable patients, the enrollment of~150 patients was targeted (50 per cohort).
Given the non-comparative nature of the study, no formal statistical comparisons between the three treatment cohorts were made.
All patients who received at least one dose of any study drug were included in the safety analyses. The response-evaluable population was defined as a subset of the intention-to-treat population with measurable disease at baseline and with at least one post baseline response assessment.
OS was calculated from the start of the treatment until the date of death or the date the patient was last known to be alive. PFS was calculated from the start of the treatment until the date of disease progression or death (regardless of the cause of death). Time-to-event analyses were performed with the Kaplan-Meier method. 21 The analyses were performed using the SAS software version 8.2 (SAS Institute, Cary NC, USA).
RESULTS

Patient characteristics
One-hundred and fifty-two patients were enrolled, 51 in the VP, 51 in the VCP and 50 in the VMP cohorts. Patient disposition is shown in Figure 1 . The median follow-up from enrollment was 27.2 months (range: 0-42 months).
The median age was 78 years (range: 59-88) with 33% of patients ⩾ 80 years of age. Overall, 27%, 29% and 44% of patients had ISS stage I, II or III disease, respectively. Eighteen percent of patients had high-risk myeloma, defined by the presence of any of t(4;14), t(14;16) or del17p13 by fluorescent in situ hybridization. According to the frailty scoring system, 4 based on age, comorbidities, cognitive and physical conditions, three groups of patients were identified: fit (score = 0, 16%); intermediate (score = 1, 30%) and frail (score ⩾ 2, 54%) (Supplementary Appendix).
Overall, 76% of patients enrolled were older than 75 years, 22% had a performance status ⩽ 70%, 11% had creatinine clearance o 30 ml/min and 52% had at least one comorbidity including cardiopulmonary, diabetes or renal disease, and thus were unsuitable for standard treatments or excluded from clinical protocols with standard inclusion/exclusion criteria. Baseline characteristics were similar between the treatment cohorts (Table 1) , except for the VP group, where a higher proportion of patients was ⩾ 80 years (41%), frail (72%) and had ISS stage III (53%).
Efficacy
One-hundred and forty-eight out of 152 patients started treatment. Four patients did not start treatment for withdrawal of consent (two patients), lost to follow-up (one patient) and patient condition (one patient) ( Figure 1 ).
The median number of cycles administered was 9 (range: 1-9), with similar distribution across groups. The median time on therapy was~11 months in all treatment groups.
Ninety-three patients across the three cohorts completed all nine cycles of induction, and 79 patients started maintenance as planned.
Overall 148 patients could be evaluated for response. After induction, the ORR was 64% with VP, 67% with VCP and 86% with VMP, including a VGPR or better of 26%, 28.5% and 49%, and a complete response (CR)/stringent CR (sCR) of 8%, 2% and 14% in the three cohorts, respectively ( Table 2 ). The median time to at least a VGPR was 5.7 months.
The median PFS was 14.0, 15.2 and 17.1 months, and the 2-year OS estimate was 60%, 70%, 76% for the VP, VCP and VMP groups, respectively ( Figure 2 ). The median PFS was 14.1 months for patients o 80 years and 16.1 for patients ⩾ 80 years, and the respective 2-year OS rates were 70% and 67%.
We examined the impact of frailty on outcome. Among patients enrolled in the VP group, the majority were frail (72%) and ⩾ 80 years (41%). More fit patients received triplet regimens. In the overall population, the median PFS was 22.4, 15.2 and 13.8 months, and the 2-year OS was 84%, 76% and 60% in fit, intermediate and frail patients, respectively. Safety One-hundred and forty-eight patients could be evaluated for toxicity. Hematological toxicity was infrequent; the rate of at least one grade ⩾ 3 hematologic AE was 6% with VP, 8% with VCP and 10% with VMP groups and they were considered drug-related according to investigators' opinion. Overall, grade 3 or higher thrombocytopenia was observed in 2% of patients.
The incidence of at least one drug-related grade ⩾ 3 nonhematologic AE was 22% with VP, 37% with VCP and 33% with VMP. The most common toxicities were infections (8-14%), mostly pulmonary; constitutional (6-10%), mostly fatigue; and cardiac events (4-8%), mostly heart failure. Grade ⩾ 3 peripheral neuropathy occurred in eight patients (5%) ( Table 3) . Five solid second primary malignancies (pancreas, bowel, breast, liver and lung) were reported: two cases were diagnosed within 6 months of start of myeloma therapy and three after more than 17 months.
At least one drug-related non-hematologic serious AE (SAE) was reported in 8%, 8% and 20% in the VP, VCP and VMP groups. The most frequent SAEs were cardiologic events (heart failure in four patients and atrial fibrillation in two patients) and infections (bronchitis in two patients, pneumonia in five patients and sepsis in one patient).
Twelve percent of patients in the VP, 14% in the VCP and 20% in the VMP groups discontinued treatment due to AEs.
Fifteen, 13 and 10 deaths occurred during induction treatment in the VP, VCP and VMP groups, respectively; among them 27%, 31% and 50% were due to AEs. Toxicity-related deaths within 60 days occurred in 3.4% of the patients, mainly due to infections (two patients) and cardiovascular events (three patients). Within 6 months of the start of therapy, 15 patients (10%) died for any cause and 8 (5%) because of AEs: infections (four patients), cardiovascular events (three patients) and one second cancer (pancreas).
At least one drug-related SAE was reported in 13% of frail patients and none in fit ones. The dropout rate during induction was higher in frail patients (55%) as compared with fit ones (28%). 
Discontinued treatment N=24
Reasons:
• Progressive disease (N=14)
• Adverse events (N=7)
• Lost to follow-up (N=1)
• Patient condition (N=1)
• Withdrawal of consent (N=1)
Discontinued treatment N=20
• Progressive disease (N=9)
• Adverse events (N=10)
• The discontinuation rate due to AEs was 26% in frail patients and 8% in fit ones. The majority of early deaths due to toxicity within 6 months of the start of therapy occurred in frail patients (5/6, 83%).
Maintenance Seventy-nine patients started maintenance, 25 in the VP, 25 in the VCP and 29 in the VMP groups. After a median follow-up of 18 months (range 1-43 months) from the initiation of maintenance, an improvement in the depth of response was observed in 14 patients (18%): one patient in CR upgraded to sCR, five patients in VGPR upgraded to CR/sCR, four patients in PR upgraded to either CR or VGPR and four patients in SD upgraded to VGPR or PR. Overall, 51% of patients had a stability of response. Response to maintenance therapy was not influenced by the previous induction regimen.
The median PFS from the start of maintenance was 27.7 months; the 2-year OS estimate was 88% (Figure 2 ).
Approximately half of frail patients enrolled in the trial started maintenance. No significant difference in PFS was observed between fit, intermediate and frail patients.
No grade 3 or higher hematologic AEs related to bortezomib were reported. At least one grade ⩾ 3 non-hematologic AE was seen in 16% of the patients; only 7.5% of them were considered related to the study drugs. The most frequent drug-related AEs were infections. The rate of discontinuation due to AEs was 14%.
DISCUSSION
To our knowledge, this is the first prospective study assessing bortezomib-based treatments in very elderly (⩾ 75 years) and frail patients with comorbidities and/or disabilities, who are usually excluded from clinical trials.
This study shows that low-dose intensity bortezomib-based regimens are well tolerated and are effective in a communitybased setting, with similar efficacy between the doublet VP and the triplets VCP and VMP. Toxicities, discontinuation rate and early deaths due to toxicity were higher in the VMP group, particularly in frail patients.
Our data compare favorably with the US community-based, phase 3b randomized, UPFRONT trial, which compared bortezomib-dexamethasone (VD), bortezomib-thalidomide-dexamethasone (VTD) and VMP, followed by weekly bortezomib maintenance, in elderly patients with newly diagnosed MM. 12 The median age was 73 years, 18% of patients were ⩾ 80 years and 48% had at least one comorbidity. All three regimens demonstrated substantial activity, with an ORR of 73%, 80% and Our results confirm these data, highlighting that the doublet therapy may be as effective as the triplets, considering both efficacy and treatment-related toxicities.
In our study, these low-dose intensity regimens were well tolerated. Only 5% of patients reported grade ⩾ 3 neuropathy and a very low incidence of severe thrombocytopenia was observed. The use of subcutaneous once-weekly bortezomib significantly reduced peripheral neuropathy, which was reported in~20% of patients treated with twice-weekly bortezomib. 12 The most common AEs included infections (8-14%) and cardiac events (4-8%), which occurred mostly in VMP patients. The incidence of infections and cardiac complications in our trial seems higher as compared with the Spanish trial in which bortezomib was administered once-weekly, but the patient populations of the two trials are not comparable (fit patients with a median age of 73 years vs frail patients with a median age of 78 years). 22 Thus, prophylactic antibiotics during the first 3-4 months of induction and a more accurate upfront cardiac screening should be considered.
In the French MPT trial designed for patients over 75 years, 45% of patients discontinued treatment for AEs. 11 In the UPFRONT study, 22-28% discontinued treatment for drug-related AEs. The toxicity profile was influenced by the use of twice-weekly bortezomib, combined with thalidomide or full-dose melphalan (9 mg/m 2 for 4 days). In our trial bortezomib was given onceweekly and melphalan at lower doses, thus producing similar responses and outcomes, but a lower toxicity, in a comparable setting. In our study, the discontinuation rate was low, from 8 to 20% in the VMP group, suggesting that a low-dose intensity treatment could be an option in this subset of patients, to avoid early discontinuation.
Concerning early deaths, 5% of patients died because of AEs and 3% because of progressive disease in the first 6 months from the start of therapy. The twofold higher risk of early deaths for toxicity as compared with disease progression confirms the need for a careful assessment of frail patients who may benefit from a gentler or even palliative approach. Furthermore, the improvement in supportive therapy together with prevention, prompt recognition and treatment of complications are urgently needed to reduce the risk of deaths due to toxicity.
In our trial, bortezomib maintenance was associated with an improvement in response, a longer PFS and very few AEs. Furthermore, during maintenance, the discontinuation rate because of any cause and particularly because of AEs was low, indicating that the schedule of bortezomib planned in this study is feasible. Previous studies have evaluated the role of frontline continuous bortezomib-based treatment. 23, 24 The Spanish trial, including fit elderly patients, evaluated bortezomib maintenance after VMP or bortezomib-thalidomide-prednisone (VTP) induction, and found that VP maintenance induced a median PFS of 32 months. In our study, maintenance therapy with bortezomib resulted in a long PFS (27.7 months), which is quite comparable with the PFS reported in fit patients.
The benefit of a continuous treatment with lenalidomide after an alkylator-based regimen was less evident in patients older than 75 years of age, 25 whereas its activity was confirmed in the continuous treatment lenalidomide-dexamethasone, irrespective of age. In our trial, the beneficial effect of bortezomib maintenance was evident irrespective of age and frailty status. In this community-based setting, a prolonged time without symptoms of disease progression and without major toxicities would translate into a physical and emotional benefit for the patient. Therefore, the final benefit of a prolonged maintenance vs a treatment-free interval remains still unknown. Thus, it would be essential in future trials to validate this hypothesis, also through quality of life studies.
Until now, advanced age was usually the only criterion to define frail patients, which sometimes led to an improper underor overtreatment of patients. In this study, no difference was observed in patients younger or older than 75 or 80 years, confirming that age is no longer sufficient to appropriately identify frail patients. As recently reported in a large analysis including also the present trial, by applying a frailty score that combines age, functional status (measured with ADL and IADL scores) and comorbidities (assessed with Charlson comorbidity index), we were able to stratify patients into fit, intermediate and frail; of note, the latter group showed an inferior survival, a higher risk of non-hematologic AEs and treatment discontinuation. 4 In the current study, the majority of patients were frail (54%), and the majority of frail and older patients (⩾ 80 years) were enrolled in the VP group.
The main limit of this non-randomized trial is that the patients were not stratified at enrollment. The unbalanced distribution of frail and older patients among the three treatment groups may, in part, explain the lower rate of response observed in the VP group. On the other hand, the approved standard treatments MPT and VMP with twice-weekly bortezomib for newly diagnosed myeloma patients induced response rates of 71% and 59%, a median PFS of 24 and 20.3 months, with a rate of treatment discontinuation for toxicity of 34-40%, respectively. 6, 7 In our study, the majority of fit patients received the triplet VMP and VCP (84%); in fit patients the response rate was 76%, the median PFS was 22.4 months and the rate of treatment discontinuation for toxicity was 8%. In frail patients treated with VMP, the discontinuation rate for toxicity was 29%. The shorter PFS observed in frail patients (13.8 months) may be due to the higher toxicity and treatment discontinuation, highlighting the difficulty in treating frail patients even with lowdose intensity regimens. These data confirm the activity of VMP or triplet bortezomib-based treatments in fit elderly patients, which still appear too toxic for frail patients.
In conclusion, the current study, with the limits of its phase 2 design, did not show a substantial advantage for the three-drug regimens. The VMP group showed significant activity, at the expense of a higher toxicity.
The growing number of older adults with myeloma is increasing the need for practical strategies to recognize and appropriately manage frail patients. The efficacy and safety results, as well as the costs associated with treatment, suggest that full-dose triplet combinations can be indicated in fit patients, where a good quality response and a prolonged PFS and OS are the goals of treatment. A doublet therapy should be preferred in frail patients, where the real goals of care are stabilization of the disease, symptoms control, preserving quality of life and independence status, rather than prolonged survival. In this setting, a doublet combination with subcutaneous bortezomib and low-dose steroid followed by maintenance could be recommended as upfront treatment.
This study represents a starting point for a prospective evaluation of two-drug regimens in frail elderly patients.
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